CYD-4-61

CYD-4-61 is a small-molecule, direct activator of the pro-apoptotic protein BAX (Bcl-2-associated X protein). Developed by researchers at the University of Texas Medical Branch and UT MD Anderson Cancer Center, CYD-4-61 was optimized from the lead compound SMBA1 to target the serine 184 (S184) phosphorylation pocket of BAX. By preventing nicotine-induced phosphorylation, it promotes BAX activation, mitochondrial outer membrane permeabilization, and cytochrome c release, triggering apoptosis in cancer cells. CYD-4-61 has demonstrated potent submicromolar antiproliferative activity against breast cancer cell lines (including triple-negative MDA-MB-231 and ER-positive MCF-7) and has shown in vivo efficacy in suppressing xenograft tumor growth. Additionally, research has shown that CYD-4-61 can suppress gastric adenocarcinoma growth and enhance anti-PD-1 immunotherapy responses by inhibiting the SOX9-CDK4 oncogenic axis.

Other names

compound 49compound49compound-49